BMY-28100 IN CUTANEOUS BACTERIAL INFECTIONS
スポンサーリンク
概要
- 論文の詳細を見る
BMY-28100, a new cephalosporin antibiotic was studied clinically and basically in bacteriological skin infections.<BR>1) In a clinical study, BMY-28100 was administered orally at 750mg t. i. d. or 500mg b. i. d. to 15 adult patients with various bacterial dermatoses: folliculitis (3), furuncle (3), erysipelas (1), lymphangitis (1), whitlow (3), infectious atheroma (2) and secondary infection (2). Clinical results were recovery in 5, significant improvement in 4, improvement in 3, slight improvement in 2 and no change in 1. No side effects were observed. In laboratory findings, a slight increase in BUN was noticed in one case.<BR>2) <I>Staphylococcus aureus</I> (6), methicillin resistant <I>S. aureus</I> (MRSA)(2), coagulase-negative staphylococci (CNS)(3), <I>S. aureus</I> plus CNS (1), <I>S. aureus</I> plus <I>Klebsiella pneumoniae</I> (1), <I>Escherichia coli</I> (1) and <I>Klebsiella oxytoca</I> (1) were isolated from clinical specimens. Minimum inhibitory concentrations of BMY-28100, cefaclor, cefadroxil, ampicillin and amoxicillin against these bacteria were measured. BMY-28100 proved to be superior to the other drugs against isolated organisms.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.